IMMUPHARMA PLC — Regulatory Filings 2018

Mar 5, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7432G

Immupharma PLC

05 March 2018

5 March 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

AIM Rule 17 Notice

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

-Ends-

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations lisa.baderoon@immupharma.com Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) David Hignell, Dugald J. Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

AMOEAKDSEFFPEFF